Patent US1979966A successfully refreshed from Google Patents.
Patent EP0507187A1 successfully refreshed from Google Patents.
EP0507187A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for inhibiting pulmonary oxygen toxicity
Assignee: Boehringer Ingelheim Pharmaceuticals Inc
•
Filing: 1992-03-24
•
Granted: —
•
Expires: 2012-03-24
Abstract
Abstract A method for inhibiting pulmonary oxygen toxicity in a patient requiring elevated levels of inhaled oxygen, by prophylactic administration of certain adhesion molecules and antibodies thereto.
Inventors
- 👤 Craig D. Wegner
- 👤 L. Gordon Letts
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 17:52
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; C07K16/2821; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/177; A61K38/1774; A61K38/1777; A61P; A61P11/00; A61P11/16; A61P43/00; A61P7/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
131 words
The use of an agent selected from the group consisting of: a) an antibody capable of binding to ICAM-1; b) a fragment of the antibody (a), the fragment being capable of binding to ICAM-1; c) ICAM-1, being substantially free of natural contaminants; d) a functional derivative of ICAM-1; e) an antibody capable of binding to a member of the CD18 family of glycoproteins; f) a fragment of the antibody (e), the fragment being capable of binding to a member of the CD18 family of glycoproteins; g) a member of the CD18 family of glycoproteins, being substantially free of natural contaminants; and h) a functional derivative of a member of the CD18 family of glycoproteins in the manufacture of a pharmaceutical preparation for inhibiting pulmonary oxygen toxicity in a patient susceptible thereto.
Claim 2
Dependent Claim
32 words
The use of claim 1 wherein the agent is the antibody (a) capable of binding to ICAM-1, or a fragment of the antibody (a), the fragment being capable of binding to ICAM-1.
Claim 3
Dependent Claim
13 words
The use of claim 2 wherein the antibody (a) is a monoclonal antibody.
Claim 4
Dependent Claim
16 words
The use of claim 1 wherein the agent is ICAM-1, being substantially free of natural contaminants.
Claim 5
Dependent Claim
14 words
The use of claim 1 wherein the agent is a functional derivative of ICAM-1.
Claim 6
Dependent Claim
18 words
The use of claim 5 in which the functional derivative of ICAM-1 is a soluble derivative of ICAM-1.
Claim 7
Dependent Claim
46 words
The use of claim 1 wherein the agent is the antibody (e) capable of binding to a member of the CD18 family of glycoproteins; or a fragment of the antibody (e), the fragment being capable of binding to a member of the CD18 family of glycoproteins.
Claim 8
Dependent Claim
26 words
The use of claim 7 wherein the antibody (e) is able to bind to an alpha subunit of the member of the CD18 family of glycoproteins.
Claim 9
Dependent Claim
26 words
The use of claim 7 wherein the antibody (e) is able to bind to a beta subunit of the member of the CD18 family of glycoproteins.
Claim 10
Dependent Claim
23 words
The use of claim 1 wherein the agent is a member of the CD18 family of glycoproteins, being substantially free of natural contaminants.
Claim 11
Dependent Claim
27 words
The use of claim 10 wherein the member of the CD18 family of glycoproteins contains an alpha subunit of a member of the CD18 family of glycoproteins.
Claim 12
Dependent Claim
27 words
The use of claim 10 wherein the member of the CD18 family of glycoproteins contains a beta subunit of a member of the CD18 family of glycoproteins.
Claim 13
Dependent Claim
31 words
The use of claim 10 wherein the member of the CD18 family of glycoproteins is a heterodimer containing both an alpha and a beta subunit of the CD18 family of glycoproteins.
Claim 14
Dependent Claim
21 words
The use of claim 10 wherein the agent is a functional derivative of a member of the CD18 family of glycoproteins.
References Cited (Backward Citations)
EP0346078A2
Cited
EP0387701B1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.